Cargando…

Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge

BACKGROUND: The co-occurrence of type 1 autoimmune pancreatitis (AIP) and pancreatic tumor (PaT) has been previously reported. Pure AIP cases have favorable prognosis and are primarily treated with steroids, while AIP cases with PaT are associated with poor prognosis where the primary management is...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Pei, Zhang, Xiaoling, Wang, Chaoyang, Lang, Yuejiao, Xu, Ling, Huang, Li, Shen, Jingxian, Feng, Shi-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698045/
https://www.ncbi.nlm.nih.gov/pubmed/31419961
http://dx.doi.org/10.1186/s12885-019-6027-0
_version_ 1783444482479357952
author Xiang, Pei
Zhang, Xiaoling
Wang, Chaoyang
Lang, Yuejiao
Xu, Ling
Huang, Li
Shen, Jingxian
Feng, Shi-Ting
author_facet Xiang, Pei
Zhang, Xiaoling
Wang, Chaoyang
Lang, Yuejiao
Xu, Ling
Huang, Li
Shen, Jingxian
Feng, Shi-Ting
author_sort Xiang, Pei
collection PubMed
description BACKGROUND: The co-occurrence of type 1 autoimmune pancreatitis (AIP) and pancreatic tumor (PaT) has been previously reported. Pure AIP cases have favorable prognosis and are primarily treated with steroids, while AIP cases with PaT are associated with poor prognosis where the primary management is pancreatic resection. However, it’s a challenge to timely identify the concurrent PaT in AIP because of their similar clinical and radiological manifestations. METHODS: We retrospectively reviewed the data in two medical centers from January 2010 to April 2019. The inclusion criteria were as follows: 1) completion of abdominal CT imaging before invasive procedures to the pancreas, 2) a final diagnosis of type 1 AIP using the 2011 international consensus diagnostic criteria, 3) follow-up duration of at least one month unless AIP and PaT were identified simultaneously. The presence of PaT in AIP was made based on histopathological confirmation, and the absence of PaT in AIP was defined as no pathological or radiological evidence of concurrent PaT. Clinical and radiological characteristics including gender, age, surveillance period, serum IgG4 and Ca-199 levels, biopsy, extrapancreatic involvement, CT and MR (if performed) imaging characteristics were compared between AIP with and without PaT. The Fisher’s exact test was used for qualitative variables, and nonparametric Mann-Whitney test for quantitative variables. A p value ≤0.05 was considered statistically significant. RESULTS: A total of 74 patients with type 1 AIP were included, of which 5 (6.7%) had the concurrent PaT. The subtypes were pancreatic ductal adenocarcinoma (3/5), solitary extramedullary plasmacytoma in the pancreas (1/5) and cholangiocarcinoma in the pancreatic segment (1/5), respectively. Gender (p = 0.044), the pattern of pancreatic enlargement (p = 0.003), heterogeneity (p = 0.015), low-density (p = 0.004) on CT and rim enhancement on MRI (p = 0.050) differed significantly between AIP with and without PaT. None of the low-density characteristics on CT or other assessed MRI characteristics could significantly differentiate the two groups (p>0.05). CONCLUSIONS: Female, focal pancreatic enlargement, pancreatic heterogeneity, low-density on CT and rim enhancement on MRI are suggestive of the concurrent PaT in type 1 AIP. The characteristics of low-density on CT or other MRI characteristics did not provide further diagnostic values.
format Online
Article
Text
id pubmed-6698045
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66980452019-08-19 Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge Xiang, Pei Zhang, Xiaoling Wang, Chaoyang Lang, Yuejiao Xu, Ling Huang, Li Shen, Jingxian Feng, Shi-Ting BMC Cancer Research Article BACKGROUND: The co-occurrence of type 1 autoimmune pancreatitis (AIP) and pancreatic tumor (PaT) has been previously reported. Pure AIP cases have favorable prognosis and are primarily treated with steroids, while AIP cases with PaT are associated with poor prognosis where the primary management is pancreatic resection. However, it’s a challenge to timely identify the concurrent PaT in AIP because of their similar clinical and radiological manifestations. METHODS: We retrospectively reviewed the data in two medical centers from January 2010 to April 2019. The inclusion criteria were as follows: 1) completion of abdominal CT imaging before invasive procedures to the pancreas, 2) a final diagnosis of type 1 AIP using the 2011 international consensus diagnostic criteria, 3) follow-up duration of at least one month unless AIP and PaT were identified simultaneously. The presence of PaT in AIP was made based on histopathological confirmation, and the absence of PaT in AIP was defined as no pathological or radiological evidence of concurrent PaT. Clinical and radiological characteristics including gender, age, surveillance period, serum IgG4 and Ca-199 levels, biopsy, extrapancreatic involvement, CT and MR (if performed) imaging characteristics were compared between AIP with and without PaT. The Fisher’s exact test was used for qualitative variables, and nonparametric Mann-Whitney test for quantitative variables. A p value ≤0.05 was considered statistically significant. RESULTS: A total of 74 patients with type 1 AIP were included, of which 5 (6.7%) had the concurrent PaT. The subtypes were pancreatic ductal adenocarcinoma (3/5), solitary extramedullary plasmacytoma in the pancreas (1/5) and cholangiocarcinoma in the pancreatic segment (1/5), respectively. Gender (p = 0.044), the pattern of pancreatic enlargement (p = 0.003), heterogeneity (p = 0.015), low-density (p = 0.004) on CT and rim enhancement on MRI (p = 0.050) differed significantly between AIP with and without PaT. None of the low-density characteristics on CT or other assessed MRI characteristics could significantly differentiate the two groups (p>0.05). CONCLUSIONS: Female, focal pancreatic enlargement, pancreatic heterogeneity, low-density on CT and rim enhancement on MRI are suggestive of the concurrent PaT in type 1 AIP. The characteristics of low-density on CT or other MRI characteristics did not provide further diagnostic values. BioMed Central 2019-08-16 /pmc/articles/PMC6698045/ /pubmed/31419961 http://dx.doi.org/10.1186/s12885-019-6027-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Xiang, Pei
Zhang, Xiaoling
Wang, Chaoyang
Lang, Yuejiao
Xu, Ling
Huang, Li
Shen, Jingxian
Feng, Shi-Ting
Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge
title Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge
title_full Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge
title_fullStr Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge
title_full_unstemmed Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge
title_short Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge
title_sort pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698045/
https://www.ncbi.nlm.nih.gov/pubmed/31419961
http://dx.doi.org/10.1186/s12885-019-6027-0
work_keys_str_mv AT xiangpei pancreatictumorintype1autoimmunepancreatitisadiagnosticchallenge
AT zhangxiaoling pancreatictumorintype1autoimmunepancreatitisadiagnosticchallenge
AT wangchaoyang pancreatictumorintype1autoimmunepancreatitisadiagnosticchallenge
AT langyuejiao pancreatictumorintype1autoimmunepancreatitisadiagnosticchallenge
AT xuling pancreatictumorintype1autoimmunepancreatitisadiagnosticchallenge
AT huangli pancreatictumorintype1autoimmunepancreatitisadiagnosticchallenge
AT shenjingxian pancreatictumorintype1autoimmunepancreatitisadiagnosticchallenge
AT fengshiting pancreatictumorintype1autoimmunepancreatitisadiagnosticchallenge